Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 12c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.36), $0.12 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $83.27 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• FOMC minutes from July 28-29th meeting
• Active options: TSLA NVDA AAPL AMZN INTC MU MSFT MSTR SPCX META
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance